Oncolytic viruses in melanoma.

Journal Article (Journal Article;Review)

Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases. This diverse spectrum of disease requires a personalized approach to management and has resulted in the development of both local (e.g., surgery, radiation, intralesional injection) and systemic (intravenous or oral) treatment strategies. Intralesional agents such as oncolytic viruses may also evoke local immune stimulation to induce and enhance the antitumor immune response. Further, it is hypothesized that these oncolytic viruses may convert immunologically "cold" tumors to more reactive "hot" tumor microenvironments and thereby overcome anti-PD-1 therapy resistance. Currently, talimogene laherparepvec (T-VEC), a modified herpes virus, is FDA-approved in this population, with many other oncolytic viruses under investigation in both preclinical and trial settings. Herein, we detail the scientific rationale, current landscape, and future directions of oncolytic viruses in melanoma.

Full Text

Duke Authors

Cited Authors

  • Robinson, C; Xu, MM; Nair, SK; Beasley, GM; Rhodin, KE

Published Date

  • February 14, 2022

Published In

Volume / Issue

  • 27 / 2

Start / End Page

  • 63 -

PubMed ID

  • 35227006

Electronic International Standard Serial Number (EISSN)

  • 2768-6698

Digital Object Identifier (DOI)

  • 10.31083/j.fbl2702063


  • eng

Conference Location

  • Singapore